Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Net Margin (2020 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Net Margin for 6 consecutive years, with 9.22% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 1536.0% to 9.22% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 18.27% through Dec 2025, down 208.0% year-over-year, with the annual reading at 18.27% for FY2025, 208.0% down from the prior year.
  • Net Margin hit 9.22% in Q4 2025 for Harmony Biosciences Holdings, down from 21.24% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 75.03% in Q3 2022 to a low of 11.92% in Q3 2021.
  • Historically, Net Margin has averaged 22.12% across 5 years, with a median of 24.29% in 2023.
  • Biggest five-year swings in Net Margin: soared 25968bps in 2021 and later crashed -5103bps in 2023.
  • Year by year, Net Margin stood at 24.9% in 2021, then surged by 52bps to 37.81% in 2022, then tumbled by -79bps to 7.83% in 2023, then soared by 214bps to 24.58% in 2024, then plummeted by -62bps to 9.22% in 2025.
  • Business Quant data shows Net Margin for HRMY at 9.22% in Q4 2025, 21.24% in Q3 2025, and 19.84% in Q2 2025.